NCT02442427.

Trial name or title	Palivizumab therapy for RSV‐bronchiolitis
Methods	Randomised placebo‐controlled trial
Participants	Infants 3 years of age or younger presenting to an emergency department with acute bronchitis and positive RSV rapid antigen test
Interventions	Single‐dose intravenous palivizumab versus saline placebo comparator
Outcomes	Readmission during 3‐week follow‐up after discharge
Starting date	September 2014
Contact information	Information provided by: Hamad Medical Corporation
Notes	Sponsor: Hamad Medical Corporation

RSV: respiratory syncytial virus